LivaNova to Present Autonomic Regulation Therapy Findings for Chronic Heart Failure Patients at the American College of Cardiology 68th Annual Scientific Session
The LivaNova VITARIA® System delivers Autonomic Regulation Therapy (ART) using Vagus Nerve Stimulation (VNS) to treat patients with chronic, symptomatic heart failure with reduced ejection fraction (HFrEF). VITARIA is currently being used to study the effects of ART in a prospective, international, randomized, controlled clinical trial (ANTHEM-HFrEF Pivotal Study). Patients meeting all inclusion and exclusion criteria are randomized (2:1) to either the treatment arm or the control arm, and are followed thereafter to determine the safety and efficacy of the system and therapy.
“LivaNova is dedicated to changing lives through development and commercial introduction of innovative solutions, like the VITARIA System, which is the first system to deliver therapeutic levels of Autonomic Regulation Therapy through Vagus Nerve Stimulation,” said
The VITARIA System has received Expedited Access Pathway designation as a Breakthrough Technology from the
“The results from this landmark study have the potential to fundamentally alter the paradigm of treating chronic heart failure,” said Dr.
Three posters related to long-term follow-up and dosing of ART in the ANTHEM-HF Pilot Study will be presented during Scientific Sessions of ACC 2019 on
“Long-term Follow-up of Reduced Ejection Fraction Heart Failure Patients Receiving Autonomic Regulation Therapy in the ANTHEM-HF Pilot Study”
“Comparison of Background Pharmacologic Therapy in the ANTHEM-HF Pilot Study to Contemporary Trials of Novel Heart Failure Therapies”
“Quantitative Assessment of Transient Heart Rate Dynamics in Patients Exposed to Chronic Autonomic Regulation Therapy Provides Evidence of Durable Neuromodulation Resulting from Cyclic Stimulation of the Vagus Nerve”
To learn more about the LivaNova VITARIASystem and the treatment of heart failure with ART, visit www.ARTforHeartFailure.com.
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs approximately 4,000 employees. LivaNova operates as two businesses: Cardiovascular and Neuromodulation, with operating headquarters in Mirandola (
For more information, please visit www.livanova.com.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe LivaNova’s future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, "may," “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this news release are based on information presently available to
All information in this news release is as of the date of its release.
Deanna Wilke, +1 (281) 727-2764
Director, Corporate Communications